首页> 外文期刊>Japanese Journal of Pharmacology >Interaction of Orally Administered 5-{3-[((2S)-1, 4-Benzodioxan 2-ylmethyl)amino] propoxy} -1, 3-benzodioxole (MKC-242)with 5-HT1A Receptors in Rat Brain
【24h】

Interaction of Orally Administered 5-{3-[((2S)-1, 4-Benzodioxan 2-ylmethyl)amino] propoxy} -1, 3-benzodioxole (MKC-242)with 5-HT1A Receptors in Rat Brain

机译:口服给药的5- {3-[(((2S)-1,4-Benzodioxan 2-ylmethyl)amino] propoxy} -1,3-benzodioxole(MKC-242)与5-HT1A受体在大鼠脑中的相互作用

获取原文
获取外文期刊封面目录资料

摘要

References(29) Cited-By(3) The present study was carried out to clarify whether orally administered 5-{3-[((2S)-1, 4-benzodioxan-2-ylmethyl)amino]propoxy}-1, 3-benzodioxole (MKC-242), a serotonin1A (5-HT1A)-receptor agonist having potent anxiolytic-like and antidepressant-like effects in animal models, binds to 5-HT1A receptors in rat brain. Quantitative autoradiography showed that orally administered MKC-242 (0.1-0.5 mg/kg)caused a significant decrease in [3H]8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)binding in the hippocampus and dorsal raphe nucleus sections. The decrease in the binding by MKC-242 was observed up to 4 hr after administration, and the effective doses were similar to those in its anxiolytic-like effect in the animal models. Repeated treatment of MKC-242 (0.5 mg/kg/day, p.o.)or buspirone (30 mg/kg/day, p.o.)for 2 weeks did not affect [3H]8-OH-DPAT binding in both sections. These results suggest that orally administered MKC-242 at the low doses that do not show 5-HT1A-receptor-mediated in vivo responses such as the hypothermic effect, adrenocortical effect and the decrease in 5-HT turnover passes the blood-brain barrier and subsequently binds to 5-HT1A receptors in rat brain. In addition, they indicate that repeated stimulation of the receptors by the agonists does not affect the number of the binding sites.
机译:参考文献(29)引用本(3)进行本研究是为了阐明是否口服口服5- {3-[(((2S)-1,4-benzodioxan-2-ylmethyl)amino] propoxy} -1,3 -苯并二恶唑(MKC-242)是一种5-羟色胺1A(5-HT1A)受体激动剂,在动物模型中具有有效的抗焦虑和抗抑郁作用,可与大鼠脑中的5-HT1A受体结合。定量放射自显影显示,口服海马MKC-242(0.1-0.5 mg / kg)导致[3H] 8-羟基-2-(二正丙基氨基)四氢萘(8-OH-DPAT)结合显着降低和背缝核切片。在给药后直至4小时观察到MKC-242的结合减少,并且有效剂量类似于在动物模型中的抗焦虑样作用。重复处理MKC-242(0.5 mg / kg /天,口服)或丁螺环酮(30 mg / kg /天,口服)2周均不影响[3H] 8-OH-DPAT的结合。这些结果表明,以低剂量口服给药的MKC-242不会表现出5-HT1A受体介导的体内反应,例如低温效应,肾上腺皮质效应和5-HT转换的减少都通过了血脑屏障和随后与大鼠脑中的5-HT1A受体结合。另外,它们表明激动剂对受体的重复刺激不影响结合位点的数目。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号